U.S. officials plan to release 6.4 million Covid-19 vaccine doses nationwide in an initial distribution after the first one is cleared by regulators for emergency use.
U.S. healthcare workers and others recommended for the nation’s first Covid-19 inoculations could start getting shots within a day or two of regulatory consent in December, a top official of the government’s vaccine development effort said.
Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.
Gilead’s remdesivir should not be used for patients hospitalized with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said.
With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?
Topline results from Gilead Sciences’ Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.
U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.
Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.
Governments and officials are voicing hopes that Covid-19 vaccines could bring “herd immunity”, with some calculating that immunizing just two-thirds of a population could halt the pandemic disease and help protect whole communities or nations.
BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.